Cargando…
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions...
Autores principales: | Fattizzo, Bruno, Levati, Giorgia Virginia, Giannotta, Juri Alessandro, Cassanello, Giulio, Cro, Lilla Marcella, Zaninoni, Anna, Barbieri, Marzia, Croci, Giorgio Alberto, Revelli, Nicoletta, Barcellini, Wilma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980524/ https://www.ncbi.nlm.nih.gov/pubmed/35392224 http://dx.doi.org/10.3389/fonc.2022.795955 |
Ejemplares similares
-
Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients
por: Fattizzo, Bruno, et al.
Publicado: (2020) -
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy
por: Barcellini, Wilma, et al.
Publicado: (2020) -
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
por: Cassanello, Giulio, et al.
Publicado: (2022) -
Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020) -
Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022)